Bayerische Motoren Werke ADR (BMWYY)

In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC ) is answering this call with pioneering RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers.

Shopping for a car can feel stressful, but it doesn’t have to be. At CarHub North York Chrysler, the focus is on making the entire experience easy and straightforward. It is one of the best Chrysler, Jeep, Dodge, RAM and Fiat dealerships in Ontario. They make buying, selling, financing, and servicing your car simple, transparent, and even enjoyable.

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company, announced the official launch of its Florida Sunshine brand of premium vitamins and supplements across U.S., UK, and European markets, with expansion to China via Alibaba’s Tmall Global expected in Q4 2025. Supported by AI-powered digital advertising and dedicated e-commerce storefronts, the rollout targets rising global demand for preventive health and wellness products. The Made-in-USA liposomal formulations include vitamins C and D3, CoQ10, and Lutein, offering advanced absorption technology for immunity, heart health, and overall wellness. CEO David Phipps said the launch positions NextPlat to capture significant growth opportunities in the multibillion-dollar nutraceuticals market.

UCLA researchers have developed a smart pen that can detect Parkinson’s during its early stages when the symptoms relied upon for the usual way to diagnose it haven’t shown up yet. Initial tests of this pen revealed an accuracy rate of 96.22%.

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the detection and treatment of breast cancer, has launched a new Frequently Asked Questions page on its corporate website at www.izocorp.com/faq . The resource provides accessible information on the company’s IzoView Breast CT Imaging System, development milestones, and competitive positioning, addressing topics such as breast density, imaging workflow, and comparisons with other modalities. Optimized for search and AI platforms, the FAQ page supports Izotropic’s investor relations, clinical outreach, and advocacy initiatives.

Miami is a glamorous city that is also associated with energy and sophistication. It has been a haven of business executives, celebrities, and global travelers since its lively nightlife and its white sand beaches. To the people coming into Miami International Airport (MIA), the trip cannot just begin as you get into downtown. Rather, it […]

Northridge, CA () September 15, 2025 -- George’s Alignment & Brake Service is expanding its presence to better serve drivers in Northridge and surrounding neighborhoods.

In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness plans for a technology that could transform how heart health is monitored both in clinical and home settings ( https://ibn.fm/dz7rY ).

Researchers at University of Pittsburg have found that patients who consume sucralose regularly have a lower likelihood of benefiting from immunotherapy and having longer survival times. Sucralose is an artificial sweetener that is commonly used in a variety of diet products, such as Splenda. This research is the first to connect the dietary choices that people make to groundbreaking cancer treatments.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced it will host a key opinion leader event on Sept. 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. CEO Dr. John Yu said the event will highlight safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives underscoring the compound’s potential role in addressing cancer drug resistance.

On Tuesday, the U.S. federal administration published a report aimed at improving the health of children in the country. The report calls for wide-ranging policy changes and executive actions to tackle the chronic disease burden rising in the country. HHS Secretary Kennedy Jr. announced this report. However, reactions to the contents of the report have been mixed .

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the more accurate screening, diagnosis and treatment of breast cancers, announced its sponsored placement in a MarketScreener.com editorial titled From Healthcare to Automation: Investing In Next AI Wave . The article discusses the growing adoption of specialized AI applications across industries and features Izotropic’s IzoView technology as a rare early-stage medtech opportunity with the potential to establish a new standard of care in breast cancer imaging.

Download Workshop Manuals, the premier online destination for professional automotive repair documentation since 2005, today announced a major expansion of its digital workshop manual library, adding comprehensive coverage for the latest 2024-2025 model year vehicles across all major automotive segments.

The MeatStick V Wireless Smart Meat Thermometer has been honored with the Red Dot Award: Product Design 2025 in the Kitchen Appliances category, one of the world’s most respected design competitions.

For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart’s electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately.

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary RADR(R) AI platform, is featured in the latest episode of IBN’s BioMedWire Podcast. President, CEO and Director Panna Sharma discusses the company’s mission to accelerate cancer drug development using AI, outlines progress across three ongoing clinical trials and shares his outlook on the future of precision neuro-oncology.

The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially important.

Gyre Therapeutics (NASDAQ: GYRE) has made strong progress through the first three quarters of FY2025, according to a report by Noble Capital Markets Senior Vice President and Equity Research Analyst Robert LeBoyer. The company posted continued sales growth from two recently launched products, submitted an application for Hydronidone approval in China, and initiated a U.S. Phase 2 trial for the drug. Gyre also named Dr. Han Ying, a board member since January 2025, as CEO. Phase 3 data for Hydronidone in chronic hepatitis B-associated fibrosis met its primary endpoint of fibrosis regression, supporting an NMPA filing in 3Q25. With Breakthrough Therapy Designation, approval is anticipated in 2H26, followed by commercial launch in FY2027.

Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline ( https://ibn.fm/YGu4N ). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that lack adequate treatment options while simultaneously developing critical vaccines and countermeasures for emerging infectious threats and bioterrorism risks. This combination sets the company apart as both a champion for underserved patient populations and a strategic partner in global public health preparedness.

Two former officials at the NIH have filed whistleblower complaints in which they allege that their removal from office was a result of their resistance to giving politics priority over science and their efforts to defend vaccines and research grants. They filed their complaints last week.

The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents to prevent misuse, abuse and accidental exposure of drugs with high abuse potential, particularly opioids ( ibn.fm/1qrav ). With AVERSA(TM), Nutriband is aiming to transform traditional transdermal patches into safer tools for patients who require powerful pain relief, while simultaneously reducing the risks that have fueled a national epidemic.

Luxury electric cars in India may soon become more expensive for consumers if an Indian tax panel’s recommendation for additional levies on luxury EVs goes through. According to a government document, the tax panel is proposing higher consumer levies for electric cars that cost more than $46,000, a move designed to boost consumption of locally produced goods at the expense of foreign companies like Tesla, BYD, BMW, and Mercedes-Benz.

The NCI, or National Cancer Institute, a federal body, has revealed that it will no longer fund a program that has been running for 26 years focused on advancing clinical studies on children with brain cancers.

Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease ( https://ibn.fm/0t1aK ). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing reputation as a late-stage biopharmaceutical innovator dedicated to tackling serious, underserved conditions.

Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of a landmark technical primer on transportability methods in oncology real-world evidence (RWE) in the Journal of Comparative Effectiveness Research . Co-authored by CTO Alind Gupta and CEO Paul Arora, the paper showcases how advanced statistical and AI-driven frameworks can bridge data gaps, accelerate health technology assessments, and improve global access to life-saving therapies. With the oncology RWE market projected to expand from $789 million in 2024 to $3.51 billion by 2035 at a CAGR of 14.7%, the publication underscores Fifty1 Labs’ leadership in advancing drug repurposing and treatment access, particularly in rare diseases and underserved regions.